Welcome to our dedicated page for Mainz Biomed NV SEC filings (Ticker: MYNZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mainz Biomed N.V. (NASDAQ: MYNZ) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer, alongside AI‑generated explanations to help interpret them. Mainz Biomed is a molecular genetics diagnostic company specializing in early cancer detection, and its filings provide detail on capital raising activities, share capital structure, and periodic financial reporting.
Recent Form 6‑K reports describe key financing arrangements, such as a Securities Purchase Agreement for the sale of pre‑funded units that include pre‑funded warrants and ordinary warrants, and a Placement Agency Agreement with Maxim Group LLC. Another 6‑K outlines an Equity Distribution Agreement that allows the company to sell ordinary shares through at‑the‑market offerings on the Nasdaq Capital Market or other permitted venues, with information on commission rates, offering limits, and the role of the sales agent.
Filings also cover corporate governance and share capital changes. A Deed of Amendment to the Articles of Association, reported on Form 6‑K, details adjustments to the nominal value of ordinary and preferred shares, an increase in authorized share capital within specified limits, and the elimination of fractional shares. Additional 6‑K reports make available the Management’s Discussion and Analysis of Financial Condition and Results of Operations and unaudited financial statements for defined periods, along with associated Inline XBRL data.
On this page, users can access these documents as they are furnished to the U.S. Securities and Exchange Commission through EDGAR. AI‑powered summaries highlight the main points of lengthy filings, explain the implications of capital markets transactions, and point out where financial statements and management commentary can be found. Investors can also monitor how equity distribution programs, warrant offerings, and amendments to share capital may affect the company’s capital structure over time, all within a single, organized view of Mainz Biomed’s SEC reporting history.
Mainz Biomed N.V. entered into a private placement with investor David Lazar for 6.0 USD million of convertible non-redeemable preferred stock, funded in two tranches of 3.0 USD million each. The first 3.0 USD million closed at 1.00 USD per preferred share; the second 3.0 USD million is expected after stockholder approvals at 1.50 USD per preferred share.
The preferred shares are highly dilutive: upon full conversion after required approvals, the First Closing Shares would represent about 55.4% and the Second Closing Shares about 90.2% of issued and outstanding ordinary shares on a fully diluted basis, or roughly 95.6% combined. Until conversion approval, a 19.99% beneficial ownership cap applies.
Net proceeds are earmarked for operations, working capital, and addressing liabilities. The company plans to focus on its U.S. pancreatic cancer detection program, explore sales of colorectal cancer screening assets, and wind down its German subsidiary. David Lazar was appointed Chair of the Board, and settlement agreements with certain officers and directors contemplate about 1.9 USD million of aggregate payments upon the final closing.
Mainz Biomed N.V. disclosed that it has completed share sales under a prospectus supplement tied to its equity distribution agreement with Maxim Group LLC. From January 5, 2026 through January 23, 2026, the company sold 1,735,194 ordinary shares on Nasdaq, generating aggregate gross proceeds of $2,152,822.40 before commissions and expenses.
The prospectus supplement allowed sales of ordinary shares up to an aggregate maximum offering price of $2,152,823, which has now been fully utilized. The broader equity distribution agreement, which permits offerings of up to $10,000,000 of ordinary shares, remains available for future sales, subject to market conditions and other factors.
Mainz Biomed N.V. Chief Financial Officer William J. Caragol filed an initial ownership report as of 01/01/2026. He reports beneficial ownership of 0 Ordinary Shares directly.
The filing lists several employee stock options to buy Ordinary Shares held directly. These include an option for 70,000 shares at an exercise price of $4.95, with 50% vested on 03/04/2025 and the remainder vesting 25% on 03/24/2026 and 25% on 03/04/2027. Additional options cover 3,899 shares at $200 (fully vested), 2,000 shares at $497.6, 1,000 shares at $302.8, and 1,000 shares at $191.2, each with four-year vesting schedules as described in the footnotes.
Mainz Biomed N.V. director Heiner Dreismann has filed an initial ownership report showing his current equity position in the company. The filing states that he directly holds employee stock options for 17,500 ordinary shares at an exercise price of $4.95, granted with 50% vesting upon grant on 03/04/2025 and the remaining 50% vesting in two 25% installments on 03/24/2026 and 03/04/2027. He also directly holds fully vested options for 250 ordinary shares at $302.8 and 1,950 ordinary shares at $200. The report shows 0 ordinary shares held directly, so his current economic exposure is through these option awards rather than owned shares.
Mainz Biomed N.V. director Gregory J. Tibbitts filed an initial Form 3 showing his beneficial holdings in the company’s securities as of 01/01/2026. He reports holding no ordinary shares directly, but does hold employee stock options over ordinary shares. One option grant covers 10,000 ordinary shares at an exercise price of $4.95, with 50% vested on 03/04/2025 and the remaining 25% tranches vesting on 03/24/2026 and 03/04/2027. He also holds fully vested options for 625 ordinary shares at $356.4 and 250 ordinary shares at $302.8, all owned directly.
Mainz Biomed N.V. filed an initial Form 3 showing Chief Executive Officer and director Guido Baechler’s beneficial ownership in the company’s securities as of 01/01/2026. He directly holds 6,362 ordinary shares.
Baechler also holds several employee stock options. One grant covers 145,000 ordinary shares at an exercise price of $4.95, with 50% vested on 03/04/2025 and the remaining 25% portions scheduled to vest on 03/24/2026 and 03/04/2027. A second grant for 11,696 ordinary shares at $200 per share is fully vested. A third grant for 2,000 ordinary shares at $302.8 per share vests over four years, with 25% vesting on 12/21/2023 and the remainder vesting monthly through 12/21/2026.
Mainz Biomed N.V. shareholder Kevin Donahue has filed an amended Schedule 13G reporting beneficial ownership of the company’s common stock. He reports holding 685,000 shares of Mainz Biomed common stock, representing 10.7% of the class, with the event triggering the filing dated 10/17/2025. Donahue has sole voting and sole dispositive power over all 685,000 shares, and no shared voting or shared dispositive power is reported. The filing is made in his capacity as an individual investor and indicates that he continues to own more than 5% of the company’s outstanding common stock.
Mainz Biomed N.V. director Kevin Donahue reported buying common stock in the company. On October 17, 2025, he purchased 685,000 shares at a price of
Mainz Biomed N.V. insider ownership has been updated in an amended Form 3. Director Kevin Donahue reports beneficial ownership of 685,000 shares of common stock, held directly. This amendment corrects a prior filing made on 01/16/2026 and is an administrative update to accurately reflect his reported holdings.
Mainz Biomed N.V. insider Donahue Kevin Michael, identified as a 10% owner, reported buying common stock. On 10/17/2025, he acquired 643,850 shares of Mainz Biomed common stock in a single open-market or private purchase transaction reported with code "P." Following this transaction, his directly held beneficial ownership stands at 643,850 shares.